Serum fructosamine concentration, insulin dose and insulin resistance index (IRI) were assessed before the diagnosis (t0) of the concurrent disease (hypercortisolism or hypothyroidism), and after 1 month (t1) and 3 months (t2) of trilostane or levothyroxine treatment. This evidence concerns the gene INS and hypothyroidism.